AGIO
Agios Pharm
NASDAQ: AGIO · HEALTHCARE · BIOTECHNOLOGY
$28.05
+13.10% today
Updated 2026-04-29
Market cap
$1.67B
P/E ratio
—
P/S ratio
30.88x
EPS (TTM)
$-7.26
Dividend yield
—
52W range
$22 – $46
Volume
1.1M
WallStSmart proprietary scores
38
out of 100
Grade: D
Sell
Investment rating
8.0
Growth
A8.5
Quality
A2.5
Profitability
F6.7
Valuation
B2/9
Piotroski F-Score
Weak
5.9
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →201 stocks currently score above 75
Price targets
Analyst target
$41.12
+46.60%
12-Month target
—
—
Intrinsic (DCF)
$47.92
Margin of safety
+42.17%
0 Strong Buy7 Buy3 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Altman Z 5.91 — safe zone
+ Revenue growth 86.10% QoQ
+ 42.17% below intrinsic value
+ Debt/equity 0.03x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-119.69M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $14.24M | $26.82M | $36.50M | $54.03M | $54.03M |
| Net income | $-231.80M | $-352.09M | $673.73M | $-412.78M | $-99.11M |
| EPS | — | — | — | — | $-7.26 |
| Free cash flow | $-314.36M | $-297.06M | $-391.53M | $-377.29M | $-119.69M |
| Profit margin | -1,627.82% | -1,312.63% | 1,845.92% | -764.01% | — |
Peer comparison
Smart narrative
Agios Pharm trades at $28.05. Our Smart Value Score of 38/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 5.91, it sits in the safe zone. TTM revenue stands at $54.03M. Our DCF model estimates intrinsic value at $47.92.
Frequently asked questions
What is Agios Pharm's stock price?
Agios Pharm (AGIO) trades at $28.05.
Is Agios Pharm overvalued?
Smart Value Score 38/100 (Grade D, Sell). DCF value $47.92.
What is the price target of Agios Pharm (AGIO)?
The analyst target price is $41.12, representing +46.6% upside from the current price of $28.05.
What is the intrinsic value of Agios Pharm (AGIO)?
Based on our DCF model, intrinsic value is $47.92, a +42.2% margin of safety versus $28.05.
What is Agios Pharm's revenue?
TTM revenue is $54.03M.
Piotroski F-Score?
2/9 — weak financial health.
Altman Z-Score?
5.91 — safe zone.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio30.88x
ROE-30.20%
Beta0.79
50D MA$29.73
200D MA$33.33
Shares out0.06B
Float0.05B
Short ratio—
Avg volume1.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—